Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riliprubart for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients
2023-509936-25-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2022
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of riliprubart in humoral rejection and graft rejection (4 cohorts), sponsored by Sanofi. Started Jun 2022; status: completed.
02
Drugs
riliprubart
03
Conditions
humoral rejectiongraft rejection
Beyond the preview
Go deeper on 2023-509936-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509936-25-00.